Department of Pediatrics Biannual Report 2008-2009

Bi-Annual Report • 29
Society, NYSDOH/MSSNY, “Immunization Update for
Health Care Professionals-2009”, Woodstock, NY, April 7,
2009.
Weiner LB: Invited Speaker – Medical Grand Rounds, Our
Lady of Lourdes Memorial Hospital, “New Considerations
for Adult Immunization”, Binghamton, NY, April 23, 2009.
Weiner LB: Invited Speaker - Orange County Medical
Society, NYSDOH/MSSNY, “Immunization Update for
Health Care Professionals-2009”, Newburgh, NY, May 12,
2009.
Weiner LB: Invited Speaker – Pediatric Associates,
“Update – Rotavirus Vaccines”, Camillus, NY, May 20, 2009.
Weiner LB: Invited Speaker – Immunization Summit
2009, “Immunization Safety & Breaking Communication
Barriers”, Albany, NY, June 30, 2009.
Weiner LB: Invited Speaker – Northeast Pediatrics ,
“Update on Prevention of Rotavirus Disease”, Ithaca, NY,
September 30, 2009.
Weiner LB: Participant – Scientific Advisory Board
Meeting, “Epidemiology of RSV Disease”, Washington, DC,
October 1-2, 2009.
Weiner LB: Invited Speaker – Broome County Pediatric
Society, “Update on RSV & Influenza”, Binghamton, NY,
October 21, 2009.
Weiner LB: Invited Speaker – Arnot Ogden Hospital,
NYSDOH/MSSNY, “A 2010 Clinician’s Guide to Influenza
and Vaccination Protocols”, Ogdensburg, NY, October 27,
2009.
Weiner LB: Invited Speaker – American Academy of
Pediatrics/NYSDOH Vaccine Summit, “Emerging Vaccines
in the Research Pipeline”, Mohonk, NY, November 6-8,
2009.
Weiner LB: Invited Speaker – SUNY Upstate Medical
University, Department of Medicine, NYSDOH/MSSNY,
“A 2010 Clinician’s Guide to Influenza and Vaccination
Protocols”, Syracuse, NY, November 23, 2009.
GRANTS AND CONTRACTS
Weiner LB
2005-2009 Comparative Immunogenicity of
Different Multivalent Component
Pertussis Vaccine Formulations Based
on a 5-component Acellular Pertussis in
Infants and Toddlers, M5A10: Principal
Investigator
2006-2008 Phase III Study for the Immunogenicity
and Consistency Evaluation of 3 Hib-
MenCY-TT Vaccine Lots and Evaluation
of Safety and Immunogenicity of GSK
Biologicals’ Haemophilus Influenzae Type
B and Neisseria Meningitidis Serogroups
C & Y-tetanus T, Hib 009/010: Principal
Investigator
2006-2008 A phase III, single-blind, Randomized,
Controlled, Multinational Study for the
Evaluation of Safety of GSK Biologicals’
Haemophilus Influenzae Type B and
Neisseria Meningitidis Serogroups
C and Y-Tetanus Toxoid Conjugate
Vaccine Combined, Hib 011/012: Principal
Investigator
2007-2008 Wyeth Pharmaceuticals: Trial
Evaluating the Safety, Tolerability,
and Immunogenicity of Three Lots of
13-valent Pneumococcal Conjugate
Vaccine in Healthy Infants, 6096A1-3005:
Principal Investigator
2007-2009 GlaxoSmithKline: A Phase II Randomized,
Observer Blind, Multicenter Study of
GlaxoSmithKline Biologicals’ Combined
Measles-Mumps-Rubella-Varicella
Vaccine (MMRV) Versus ProQuad,
According to a One Dose Schedule,
both Administered Subcutaneously
at 12-14 months, MMRV-054: Principal
Investigator
2009-2010 Merck and Company: Safety, Tolerability
and Immunogenicity of VARIVAX
(2007 Commercial VZV Bulk Process)
Administered Concomitantly with MMRII
in Healthy Children 12-23 Months of Age,
V210-057: Principal Investigator
2008-2010 Novartis: A Phase I, Open Label,
Randomized Multi-Center Study to
Evaluate the Safety and Immunogenicity
of ProQuad Vaccine When Administered
Concomitantly with Novartis
Meningococcal ACWY Conjugate Vaccine
to Healthy Toddlers, Protocol # V59P21:
Principal Investigator
2008-2010 Novartis: A Phase 3b, Open-Label,
Randomized, Parallel-Group,
MultiCenter Study to Evaluate the Safety
of Novartis MenACWY Conjugate Vaccine
when Administered with Routine Infant
Vaccinations to Healthy Infants, V59P23:
Principal Investigator
2008-2009 Tibotec: A Phase II, Open-Label Trial
to Evaluate the Safety, Tolerability
and Antiviral Activity of TMC125 in
Antiretroviral Experienced HIV-1 Infected
Children and Adolescents, TMC125-
TiDP35-C213: Principal Investigator
2006-2009 Sanofi Pasteur: An Immunogenicity,
Safety, and Non-Interference Evaluation
of Pediatric Vaccines Administered
Concomitantly with Menactra ®
(Meningococcal [Groups A, C, Y and
W-135] Polysaccharide Diphtheria Toxoid
Conjugate Vaccine) to Healthy Toddlers:
MTA37: Principal Investigator